Familial ATTR amyloidosis classification: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Familial ATTR amyloidosis}} {{CMG}}; {{AE}} ==Overview== There is no established system for the classification of [disease name]. OR [Disease name] may be clas...")
 
No edit summary
 
Line 34: Line 34:
==Classification==
==Classification==


There is no established system for the classification of [disease name].
Familiar amyloidosis may be classified according to the type of mutant protein into 6 subtypes:


OR
* transthyretin amyloidosis (TTR) 
 
* apolipoprotein AI 
[Disease name] may be classified according to [classification method] into [number] subtypes/groups:
* cystatin C 
*[Group1]
* lysozyme 
*[Group2]
* fibrinogen Aa-chain 
*[Group3]
* apolipoprotein AII
*[Group4]
 
OR
 
[Disease name] may be classified into [large number > 6] subtypes based on:
*[Classification method 1]
*[Classification method 2]
*[Classification method 3]
 
[Disease name] may be classified into several subtypes based on:
*[Classification method 1]
*[Classification method 2]
*[Classification method 3]
 
OR
 
Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
 
OR
 
'''If the staging system involves specific and characteristic findings and features:'''
 
According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
 
OR
 
The staging of [malignancy name] is based on the [staging system].
 
OR
 
There is no established system for the staging of [malignancy name].


==References==
==References==

Latest revision as of 23:16, 29 October 2019

Familial ATTR amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Familial ATTR amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Familial ATTR amyloidosis classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Familial ATTR amyloidosis classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Familial ATTR amyloidosis classification

CDC on Familial ATTR amyloidosis classification

Familial ATTR amyloidosis classification in the news

Blogs on Familial ATTR amyloidosis classification

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Familial ATTR amyloidosis classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

There is no established system for the classification of [disease name].

OR

[Disease name] may be classified according to [classification method] into [number] subtypes/groups: [group1], [group2], [group3], and [group4].

OR

[Disease name] may be classified into [large number > 6] subtypes based on [classification method 1], [classification method 2], and [classification method 3]. [Disease name] may be classified into several subtypes based on [classification method 1], [classification method 2], and [classification method 3].

OR

Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.

OR

If the staging system involves specific and characteristic findings and features: According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].

OR

The staging of [malignancy name] is based on the [staging system].

OR

There is no established system for the staging of [malignancy name].

Classification

Familiar amyloidosis may be classified according to the type of mutant protein into 6 subtypes:

  • transthyretin amyloidosis (TTR)
  • apolipoprotein AI
  • cystatin C
  • lysozyme
  • fibrinogen Aa-chain
  • apolipoprotein AII

References

Template:WH Template:WS